HIV restriction factors and mechanisms of evasion

Cold Spring Harbor Perspectives in Medicine

Volumn 2, Issue 5, 2012, Pages

  Malim, Michael H ^a   Bieniasz, Paul D ^b  

^a GUY S HOSPITAL   (United Kingdom)

^b ROCKEFELLER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; TRIPARTITE MOTIF PROTEIN 5; UBIQUITIN PROTEIN LIGASE; APOBEC3 PROTEIN, HUMAN; BST2 PROTEIN, HUMAN; CARRIER PROTEIN; CYTOSINE DEAMINASE; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; LEUKOCYTE ANTIGEN; TRIM5 PROTEIN, HUMAN; VIRUS PROTEIN;

ARTICLE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SOMATIC HYPERMUTATION; VIRUS REPLICATION; DRUG ANTAGONISM; GENETICS; HOST PATHOGEN INTERACTION; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MUTATION; PHYSIOLOGY; REGULATOR GENE; REVIEW; VIROLOGY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ANTIGENS, CD; CARRIER PROTEINS; CYTOSINE DEAMINASE; GENES, VIF; GPI-LINKED PROTEINS; HIV INFECTIONS; HIV-1; HOST-PATHOGEN INTERACTIONS; HUMANS; MUTATION; VIRAL REGULATORY AND ACCESSORY PROTEINS; VIRUS REPLICATION;

EID: 84878956988     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a006940     Document Type: Article

References (111)

1. Albin JS, Harris RS. 2010. Interactions of host APOBEC3 restriction factors with HIV-1 in vivo: Implications for therapeutics. Expert Rev Mol Med 12: e4. doi: 10. 1017/S1462399409001343.
2. Bartee E, McCormack A, Fruh K. 2006. Quantitative membrane proteomics reveals new cellular targets of viral immune modulators. PLoS Pathog 2: e107. doi: 10. 1371/journal. ppat. 0020107.
3. Bergeron JR, Huthoff H, Veselkov DA, Beavil RL, Simpson PJ, Matthews SJ, Malim MH, Sanderson MR. 2010. The SOCS-box of HIV-1 Vif interacts with ElonginBC by induced-folding to recruit its Cul5-containing ubiquitin ligase complex. PLoS Pathog 6: e1000925. doi: 10. 1371/journal. ppat. 1000925.
4. Berthoux L, Sebastian S, Sokolskaja E, Luban J. 2005. Cyclophilin A is required for TRIM5α-mediated resistance to HIV-1 in Old World monkey cells. Proc Natl Acad Sci 102: 14849-14853.
5. Best S, Le Tissier P, Towers G, Stoye JP. 1996. Positional cloning of the mouse retrovirus restriction gene Fv1. Nature 382: 826-829.
6. Bieniasz PD. 2003. Restriction factors: A defense against retroviral infection. Trends Microbiol 11: 286-291.
7. Bishop KN, Verma M, Kim EY, Wolinsky SM, Malim MH. 2008. APOBEC3G inhibits elongation of HIV-1 reverse transcripts. PLoS Pathog 4: e1000231. doi: 10. 1371/journal. ppat. 1000231.
8. Bogerd HP, Cullen BR. 2008. Single-stranded RNA facilitates nucleocapsid: APOBEC3G complex formation. RNA 14: 1228-1236.
9. Brennan G, Kozyrev Y, Hu SL. 2008. TRIMCyp expression in Old World primates Macaca nemestrina and Macaca fascicularis. Proc Natl Acad Sci 105: 3569-3574.
10. Bushman FD, Malani N, Fernandes J, D'Orso I, Cagney G, Diamond TL, Zhou H, Hazuda DJ, Espeseth AS, Konig R, et al. 2009. Host cell factors in HIV replication: Meta-analysis of genome-wide studies. PLoS Pathog 5: e1000437. doi: 10. 1371/journal. ppat. 1000437.
11. Casartelli N, Guivel-Benhassine F, Bouziat R, Brandler S, Schwartz O, Moris A. 2010. The antiviral factor APOBEC3G improves CTL recognition of cultured HIV-infected T cells. J Exp Med 207: 39-49.
12. Cen S, Peng ZG, Li XY, Li ZR, Ma J, Wang YM, Fan B, You XF, Wang YP, Liu F, et al. 2010. Small molecular compounds inhibit HIV-1 replication through specifically stabilizing APOBEC3G. J Biol Chem 285: 16546-16552.
13. Chelico L, Pham P, Calabrese P, Goodman MF. 2006. APOBEC3G DNA deaminase acts processively 3′ → 5′ on single-stranded DNA. Nat Struct Mol Biol 13: 392-399.
14. Chen KM, Harjes E, Gross PJ, Fahmy A, Lu Y, Shindo K, Harris RS, Matsuo H. 2008. Structure of the DNA deaminase domain of the HIV-1 restriction factor APOBEC3G. Nature 452: 116-119.
15. Chiu YL, Witkowska HE, Hall SC, Santiago M, Soros VB, Esnault C, Heidmann T, Greene WC. 2006. High-molecular-mass APOBEC3G complexes restrict Alu retrotransposition. Proc Natl Acad Sci 103: 15588-15593.
16. Cowan S, Hatziioannou T, Cunningham T, Muesing MA, Gottlinger HG, Bieniasz PD. 2002. Cellular inhibitors with Fv1-like activity restrict human and simian immunodeficiency virus tropism. Proc Natl Acad Sci 99: 11914-11919.
17. Diaz-Griffero F, Kar A, Perron M, Xiang SH, Javanbakht H, Li X, Sodroski J. 2007. Modulation of retroviral restriction and proteasome inhibitor-resistant turnover by changes in the TRIM5α B-box 2 domain. J Virol 81: 10362-10378.
18. Diaz-Griffero F, Qin XR, Hayashi F, Kigawa T, Finzi A, Sarnak Z, Lienlaf M, Yokoyama S, Sodroski J. 2009. A B-box 2 surface patch important for TRIM5α self-association, capsid binding avidity, and retrovirus restriction. J Virol 83: 10737-10751.
19. Douglas JL, Viswanathan K, McCarroll MN, Gustin JK, Fruh K, Moses AV. 2009. Vpu directs the degradation of the human immunodeficiency virus restriction factor BST-2/Tetherin via a βTrCP-dependent mechanism. J Virol 83: 7931-7947.
20. Dube M, Roy BB, Guiot-Guillain P, Binette J, Mercier J, Chiasson A, Cohen EA. 2010. Antagonism of tetherin restriction of HIV-1 release by Vpu involves binding and sequestration of the restriction factor in a perinuclear compartment. PLoS Pathog 6: e1000856. doi: 10. 1371/journal. ppat. 1000856.
21. Fitzpatrick K, Skasko M, Deerinck TJ, Crum J, Ellisman MH, Guatelli J. 2010. Direct restriction of virus release and incorporation of the interferon-induced protein BST-2 into HIV-1 particles. PLoS Pathog 6: e1000701. doi: 10. 1371/journal. ppat. 1000701.
22. + T lymphocytes. J Virol 66: 6489-6495.
23. Gaddis NC, Sheehy AM, Ahmad KM, Swanson CM, Bishop KN, Beer BE, Marx PA, Gao F, Bibollet-Ruche F, Hahn BH, et al. 2004. Further investigation of simian immunodeficiency virus Vif function in human cells. J Virol 78: 12041-12046.
24. Gallois-Montbrun S, Kramer B, Swanson CM, Byers H, Lynham S, Ward M, Malim MH. 2007. Antiviral protein APOBEC3G localizes to ribonucleoprotein complexes found in P bodies and stress granules. J Virol 81: 2165-2178.
25. Ganser-Pornillos BK, Chandrasekaran V, Pornillos O, Sodroski JG, SundquistWI, Yeager M. 2011. Hexagonal assembly of a restricting TRIM5α protein. Proc Natl Acad Sci 108: 534-539.
26. Gao G, Guo X, Goff SP. 2002. Inhibition of retroviral RNA production by ZAP, a CCCH-type zinc finger protein. Science 297: 1703-1706.
27. Goujon C, Malim MH. 2010. Characterization of the alpha interferon-induced postentry block to HIV-1 infection in primary human macrophages and T cells. J Virol 84: 9254-9266.
28. Goujon C, Arfi V, Pertel T, Luban J, Lienard J, Rigal D, Darlix JL, Cimarelli A. 2008. Characterization of simian immunodeficiency virus SIVSM/human immunodeficiency virus type 2 Vpx function in human myeloid cells. J Virol 82: 12335-12345.
29. Gupta RK, Hue S, Schaller T, Verschoor E, Pillay D, Towers GJ. 2009a. Mutation of a single residue renders human tetherin resistant to HIV-1 Vpu-mediated depletion. PLoS Pathog 5: e1000443. doi: 10. 1371/journal. ppat. 1000443.
30. Gupta RK, Mlcochova P, Pelchen-Matthews A, Petit SJ, Mattiuzzo G, Pillay D, Takeuchi Y, Marsh M, Towers GJ. 2009b. Simian immunodeficiency virus envelope glycoprotein counteracts tetherin/BST-2/CD317 by intracellular sequestration. Proc Natl Acad Sci 106: 20889-20894.
31. Hammonds J, Wang JJ, Yi H, Spearman P. 2010. Immunoelectron microscopic evidence for Tetherin/BST2 as the physical bridge between HIV-1 virions and the plasma membrane. PLoS Pathog 6: e1000749. doi: 10. 1371/journal. ppat. 1000749.
32. Harris RS, Bishop KN, Sheehy AM, Craig HM, Petersen-Mahrt SK, Watt IN, Neuberger MS, Malim MH. 2003. DNA deamination mediates innate immunity to retroviral infection. Cell 113: 803-809.
33. Hatziioannou T, Perez-Caballero D, Yang A, Cowan S, Bieniasz PD. 2004. Retrovirus resistance factors Ref1 and Lv1 are species-specific variants of TRIM5α. Proc Natl Acad Sci 101: 10774-10779.
34. Hatziioannou T, Princiotta M, Piatak M Jr., Yuan F, Zhang F, Lifson JD, BieniaszPD. 2006. Generation of simian-tropic HIV-1 by restriction factor evasion. Science 314: 95.
35. Hinz A, Miguet N, Natrajan G, Usami Y, Yamanaka H, Renesto P, Hartlieb B, McCarthy AA, Simorre JP, Gottlinger H, et al. 2010. Structural basis of HIV-1 tethering to membranes by the BST-2/tetherin ectodomain. Cell Host Microbe 7: 314-323.
36. Hofmann W, Schubert D, LaBonte J, Munson L, Gibson S, Scammell J, FerrignoP, Sodroski J. 1999. Species-specific, postentry barriers to primate immunodeficiency virus infection. J Virol 73: 10020-10028.
37. Holmes RK, Koning FA, Bishop KN, Malim MH. 2007. APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation. Comparisons with APOBEC3G. J Biol Chem 282: 2587-2595.
38. Hrecka K, Hao C, Gierszewska M, Swanson SK, Kesik-Brodacka M, Srivastava S, Florens L, Washburn MP, Skowronski J. 2011. Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein. Nature 474: 658-661.
39. Hu C, Saenz DT, Fadel HJ, Walker W, Peretz M, Poeschla EM. 2010. The HIV-1 central polypurine tract functions as a second line of defense against APOBEC3G/F. J Virol 84: 11981-11993.
40. Huthoff H, Autore F, Gallois-Montbrun S, Fraternali F, Malim MH. 2009. RNA-dependent oligomerization of APOBEC3G is required for restriction of HIV-1. PLoS Pathog 5: e1000330. doi: 10. 1371/journal. ppat. 1000330.
41. Iwatani Y, Chan DS, Wang F, Maynard KS, Sugiura W, Gronenborn AM, RouzinaI, Williams MC, Musier-Forsyth K, Levin JG. 2007. Deaminase-independent inhibition of HIV-1 reverse transcription by APOBEC3G. Nucleic Acids Res 35: 7096-7108.
42. Jia B, Serra-Moreno R, Neidermyer W, Rahmberg A, Mackey J, Fofana IB, Johnson WE, Westmoreland S, Evans DT. 2009. Species-specific activity of SIV Nef and HIV-1 Vpu in overcoming restriction by tetherin/BST2. PLoS Pathog 5: e1000429. doi: 10. 1371/journal. ppat. 1000429.
43. Johnson WE, Sawyer SL. 2009. Molecular evolution of the antiretroviral TRIM5 gene. Immunogenetics 61: 163-176.
44. Jouvenet N, Neil SJ, Zhadina M, Zang T, Kratovac Z, Lee Y, McNatt M, Hatziioannou T, Bieniasz PD. 2009. Broad-spectrum inhibition of retroviral and filoviral particle release by tetherin. J Virol 83: 1837-1844.
45. Kaletsky RL, Francica JR, Agrawal-Gamse C, Bates P. 2009. Tetherin-mediated restriction of filovirus budding is antagonized by the Ebola glycoprotein. Proc Natl Acad Sci 106: 2886-2891.
46. Keckesova Z, Ylinen LM, Towers GJ. 2004. The human and African green monkey TRIM5α genes encode Ref1 and Lv1 retroviral restriction factor activities. Proc Natl Acad Sci 101: 10780-10785.
47. Keckesova Z, Ylinen LM, Towers GJ. 2006. Cyclophilin A renders human immunodeficiency virus type 1 sensitive to Old World monkey but not human TRIM5 α antiviral activity. J Virol 80: 4683-4690.
48. Kim EY, Bhattacharya T, Kunstman K, Swantek P, Koning FA, Malim MH, Wolinsky SM. 2010. Human APOBEC3G-mediated editing can promote HIV-1 sequence diversification and accelerate adaptation to selective pressure. J Virol 84: 10402-10405.
49. Kirchhoff F. 2010. Immune evasion and counteraction of restriction factors by HIV-1 and other primate lentiviruses. Cell Host Microbe 8: 55-67.
50. Koning FA, Newman EN, Kim EY, Kunstman KJ, Wolinsky SM, Malim MH. 2009. Defining APOBEC3 expression patterns in human tissues and hematopoietic cell subsets. J Virol 83: 9474-9485.
51. Kozak SL, Marin M, Rose KM, Bystrom C, Kabat D. 2006. The anti-HIV-1 editing enzyme APOBEC3G binds HIV-1 RNA and messenger RNAs that shuttle between polysomes and stress granules. J Biol Chem 281: 29105-29119.
52. Kupzig S, Korolchuk V, Rollason R, Sugden A, Wilde A, Banting G. 2003. Bst-2/HM1. 24 is a raft-associated apical membrane protein with an unusual topology. Traffic 4: 694-709.
53. Laguette N, Sobhian B, Casartelli N, Ringeard M, Chable-Bessia C, Segeral E, Yatim A, Emiliani S, Schwartz O, Benkirane M. 2011. SAMHD1 is the dendritic-and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx. Nature 474: 654-657.
54. Langlois MA, Neuberger MS. 2008. Human APOBEC3G can restrict retroviral infection in avian cells and acts independently of both UNG and SMUG1. J Virol 82: 4660-4664.
55. LaRue RS, Andresdottir V, Blanchard Y, Conticello SG, Derse D, Emerman M, Greene WC, Jonsson SR, Landau NR, Lochelt M, et al. 2009. Guidelines for naming nonprimate APOBEC3 genes and proteins. J Virol 83: 494-497.
56. Le Tortorec A, Neil SJ. 2009. Antagonism to and intracellular sequestration of human tetherin by the human immunodeficiency virus type 2 envelope glycoprotein. J Virol 83: 11966-11978.
57. Lee-Kirsch MA. 2010. Nucleic acid metabolism and systemic autoimmunity revisited. Arthritis Rheum 62: 1208-1212.
58. Li X, Sodroski J. 2008. The TRIM5α B-box 2 domain promotes cooperative binding to the retroviral capsid by mediating higher-order self-association. J Virol 82: 11495-11502.
59. Liao CH, Kuang YQ, Liu HL, Zheng YT, Su B. 2007. A novel fusion gene, TRIM5-Cyclophilin A in the pig-tailed macaque determines its susceptibility to HIV-1 infection. AIDS 21 Suppl 8: S19-S26.
60. Lim ES, Malik HS, Emerman M. 2010. Ancient adaptive evolution of tetherin shaped the functions of Vpu and Nef in human immunodeficiency virus and primate lentiviruses. J Virol 84: 7124-7134.
61. Madani N, Kabat D. 1998. An endogenous inhibitor of human immunodeficiency virus in human lymphocytes is overcome by the viral Vif protein. J Virol 72: 10251-10255.
62. Malim MH. 2009. APOBEC proteins and intrinsic resistance to HIV-1 infection. Philos Trans R Soc Lond B Biol Sci 364: 675-687.
63. Mangeat B, Turelli P, Caron G, Friedli M, Perrin L, Trono D. 2003. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 424: 99-103.
64. Mansouri M, Viswanathan K, Douglas JL, Hines J, Gustin J, Moses AV, Fruh K. 2009. Molecular mechanism of BST2/tetherin downregulation by K5/MIR2 of Kaposi's sarcoma-associated herpesvirus. J Virol 83: 9672-9681.
65. Marin M, Rose KM, Kozak SL, Kabat D. 2003. HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nat Med 9: 1398-1403.
66. McNatt MW, Zang T, Hatziioannou T, Bartlett M, Fofana IB, Johnson WE, Neil SJ, Bieniasz PD. 2009. Species-specific activity of HIV-1 Vpu and positive selection of tetherin transmembrane domain variants. PLoS Pathog 5: e1000300. doi: 10. 1371/journal. ppat. 1000300.
67. Mitchell RS, Katsura C, Skasko MA, Fitzpatrick K, Lau D, Ruiz A, Stephens EB, Margottin-Goguet F, Benarous R, Guatelli JC. 2009. Vpu antagonizes BST-2-mediated restriction of HIV-1 release via β-TrCP and endo-lysosomal trafficking. PLoS Pathog 5: e1000450. doi: 10. 1371/journal. ppat. 1000450.
68. Miyagi E, Andrew AJ, Kao S, Strebel K. 2009. Vpu enhances HIV-1 virus release in the absence of Bst-2 cell surface down-modulation and intracellular depletion. Proc Natl Acad Sci 106: 2868-2873.
69. Miyagi E, Brown CR, Opi S, Khan M, Goila-Gaur R, Kao S, Walker RC Jr., HirschV, Strebel K. 2010. Stably expressed APOBEC3F has negligible antiviral activity. J Virol 84: 11067-11075.
70. Nathans R, Cao H, Sharova N, Ali A, Sharkey M, Stranska R, Stevenson M, RanaTM. 2008. Small-molecule inhibition of HIV-1 Vif. Nat Biotechnol 26: 1187-1192.
71. Neil SJ, Eastman SW, Jouvenet N, Bieniasz PD. 2006. HIV-1 Vpu promotes release and prevents endocytosis of nascent retrovirus particles from the plasma membrane. PLoS Pathog 2: e39. doi: 10. 1371/journal. ppat. 0020039.
72. Neil SJ, Sandrin V, Sundquist WI, Bieniasz PD. 2007. An interferon-α-induced tethering mechanism inhibits HIV-1 and Ebola virus particle release but is counteracted by the HIV-1 Vpu protein. Cell Host Microbe 2: 193-203.
73. Neil SJ, Zang T, Bieniasz PD. 2008. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 451: 425-430.
74. Newman RM, Hall L, Kirmaier A, Pozzi LA, Pery E, Farzan M, O'Neil SP, JohnsonW. 2008. Evolution of a TRIM5-CypA splice isoform in old world monkeys. PLoS Pathog 4: e1000003. doi: 10. 1371/journal. ppat. 1000003.
75. Nisole S, Stoye JP, Saib A. 2005. TRIM family proteins: Retroviral restriction and antiviral defence. Nat Rev Microbiol 3: 799-808.
76. Perez-Caballero D, Hatziioannou T, Yang A, Cowan S, Bieniasz PD. 2005. Human tripartite motif 5α domains responsible for retrovirus restriction activity and specificity. J Virol 79: 8969-8978.
77. Perez-Caballero D, Zang T, Ebrahimi A, McNatt MW, Gregory DA, Johnson MC, Bieniasz PD. 2009. Tetherin inhibits HIV-1 release by directly tethering virions to cells. Cell 139: 499-511.
78. Perron MJ, Stremlau M, Song B, Ulm W, Mulligan RC, Sodroski J. 2004. TRIM5α mediates the postentry block to N-tropic murine leukemia viruses in human cells. Proc Natl Acad Sci 101: 11827-11832.
79. Price AJ, Marzetta F, Lammers M, Ylinen LM, Schaller T, Wilson SJ, Towers GJ, James LC. 2009. Active site remodeling switches HIV specificity of antiretroviral TRIMCyp. Nat Struct Mole Biol 16: 1036-1042.
80. Refsland EW, Stenglein MD, Shindo K, Albin JS, Brown WL, Harris RS. 2010. Quantitative profiling of the full APOBEC3 mRNA repertoire in lymphocytes and tissues: Implications for HIV-1 restriction. Nucleic Acids Res 38: 4274-4284.
81. Sadler HA, Stenglein MD, Harris RS, Mansky LM. 2010. APOBEC3G contributes to HIV-1 variation through sublethal mutagenesis. J Virol 84: 7396-7404.
82. Sauter D, Schindler M, Specht A, Landford WN, Munch J, Kim KA, Votteler J, Schubert U, Bibollet-Ruche F, Keele BF, et al. 2009. Tetherin-driven adaptation of Vpu and Nef function and the evolution of pandemic and nonpandemic HIV-1 strains. Cell Host Microbe 6: 409-421.
83. Sawyer SL, Wu LI, Emerman M, Malik HS. 2005. Positive selection of primate TRIM5α identifies a critical species-specific retroviral restriction domain. Proc Natl Acad Sci 102: 2832-2837.
84. Sayah DM, Sokolskaja E, Berthoux L, Luban J. 2004. Cyclophilin A retrotransposition into TRIM5 explains owl monkey resistance to HIV-1. Nature 430: 569-573.
85. Schubert HL, Zhai Q, Sandrin V, Eckert DM, Garcia-Maya M, Saul L, SundquistWI, Steiner RA, Hill CP. 2010. Structural and functional studies on the extracellular domain of BST2/tetherin in reduced and oxidized conformations. Proc Natl Acad Sci 107: 17951-17956.
86. Sharp PM, Hahn BH. 2011. Origins of HIV and the AIDS pandemic. Cold Spring Harb Perspect Med doi: 10. 1101/cshperspect. a006841.
87. Sheehy AM, Gaddis NC, Choi JD, Malim MH. 2002. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418: 646-650.
88. Sheehy AM, Gaddis NC, Malim MH. 2003. The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat Med 9: 1404-1407.
89. Simon JH, Gaddis NC, Fouchier RA, Malim MH. 1998a. Evidence for a newly discovered cellular anti-HIV-1 phenotype. Nat Med 4: 1397-1400.
90. Simon JH, Miller DL, Fouchier RA, Soares MA, Peden KW, Malim MH. 1998b. The regulation of primate immunodeficiency virus infectivity by Vif is cell species restricted: A role for Vif in determining virus host range and cross-species transmission. EMBO J 17: 1259-1267.
91. Song B, Gold B, O'Huigin C, Javanbakht H, Li X, Stremlau M, Winkler C, Dean M, Sodroski J. 2005. The B30. 2(SPRY) domain of the retroviral restriction factor TRIM5α exhibits lineage-specific length and sequence variation in primates. J Virol 79: 6111-6121.
92. Stopak K, de Noronha C, Yonemoto W, Greene WC. 2003. HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Mole Cell 12: 591-601.
93. Stremlau M, Owens CM, Perron MJ, Kiessling M, Autissier P, Sodroski J. 2004. The cytoplasmic body component TRIM5α restricts HIV-1 infection in Old World monkeys. Nature 427: 848-853.
94. Stremlau M, Perron M, Welikala S, Sodroski J. 2005. Species-specific variation in the B30. 2(SPRY) domain of TRIM5α determines the potency of human immunodeficiency virus restriction. J Virol 79: 3139-3145.
95. Stremlau M, Perron M, Lee M, Li Y, Song B, Javanbakht H, Diaz-Griffero F, Anderson DJ, Sundquist WI, Sodroski J. 2006a. Specific recognition and accelerated uncoating of retroviral capsids by the TRIM5α restriction factor. Proc Natl Acad Sci 103: 5514-5519.
96. Stremlau M, Song B, Javanbakht H, Perron M, Sodroski J. 2006b. Cyclophilin A: An auxiliary but not necessary cofactor for TRIM5α restriction of HIV-1. Virology 351: 112-120.
97. Sundquist WI, Kräusslich H-G. 2011. HIV assembly, budding, and maturation. Cold Spring Harb Perspect Med doi: 10. 1101/cshperspect. a06924.
98. Van Damme N, Goff D, Katsura C, Jorgenson RL, Mitchell R, Johnson MC, Stephens EB, Guatelli J. 2008. The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. Cell Host Microbe 3: 245-252.
99. Varthakavi V, Smith RM, Bour SP, Strebel K, Spearman P. 2003. Viral protein U counteracts a human host cell restriction that inhibits HIV-1 particle production. Proc Natl Acad Sci 100: 15154-15159.
100. Virgen CA, Kratovac Z, Bieniasz PD, Hatziioannou T. 2008. Independent genesis of chimeric TRIM5-cyclophilin proteins in two primate species. Proc Natl Acad Sci 105: 3563-3568.
101. Wichroski MJ, Robb GB, Rana TM. 2006. Human retroviral host restriction factors APOBEC3G and APOBEC3F localize to mRNA processing bodies. PLoS Pathog 2: e41. doi: 10. 1371/journal. ppat. 0020041.
102. Wilson SJ, Webb BL, Ylinen LM, Verschoor E, Heeney JL, Towers GJ. 2008. Independent evolution of an antiviral TRIMCyp in rhesus macaques. Proc Natl Acad Sci 105: 3557-3562.
103. Wood N, Bhattacharya T, Keele BF, Giorgi E, Liu M, Gaschen B, Daniels M, Ferrari G, Haynes BF, McMichael A, et al. 2009. HIV evolution in early infection: Selection pressures, patterns of insertion and deletion, and the impact of APOBEC. PLoS Pathog 5: e1000414. doi: 10. 1371/journal. ppat. 1000414.
104. Wu X, Anderson JL, Campbell EM, Joseph AM, Hope TJ. 2006. Proteasome inhibitors uncouple rhesus TRIM5α restriction of HIV-1 reverse transcription and infection. Proc Natl Acad Sci 103: 7465-7470.
105. Yang H, Wang J, Jia X, McNatt MW, Zang T, Pan B, Meng W, Wang HW, BieniaszPD, Xiong Y. 2010. Structural insight into the mechanisms of enveloped virus tethering by tetherin. Proc Natl Acad Sci 107: 18428-18432.
106. Yap MW, Nisole S, Lynch C, Stoye JP. 2004. Trim5α protein restricts both HIV-1 and murine leukemia virus. Proc Natl Acad Sci 101: 10786-10791.
107. Yap MW, Nisole S, Stoye JP. 2005. A single amino acid change in the SPRY domain of human Trim5α leads to HIV-1 restriction. Curr Biol 15: 73-78.
108. Yu X, Yu Y, Liu B, Luo K, Kong W, Mao P, Yu XF. 2003. Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 302: 1056-1060.
109. Yu Q, Konig R, Pillai S, Chiles K, Kearney M, Palmer S, Richman D, Coffin JM, Landau NR. 2004. Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome. Nat Struct Mol Biol 11: 435-442.
110. Zhang H, Yang B, Pomerantz RJ, Zhang C, Arunachalam SC, Gao L. 2003. The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature 424: 94-98.
111. Zhang F, Wilson SJ, Landford WC, Virgen B, Gregory D, Johnson MC, Munch J, Kirchhoff F, Bieniasz PD, Hatziioannou T. 2009. Nef proteins from simian immunodeficiency viruses are tetherin antagonists. Cell Host Microbe 6: 54-67